New Tool: ProSource
Checkout our packaging and processing solutions finder, ProSource.
Start Your Search

Quick Hits: FDA Says Zantac Doesn’t Form Carcinogens in Patients

The Food and Drug Administration’s tests indicate that the popular heartburn drug does not cause carcinogens to form in users.

A recent NBC News article discussed the latest in its investigation into possible contaminants found in the popular heartburn drug Zantac. Tests conducted by the FDA found that the drug does not cause carcinogens to form in patients. The director of the FDA’s Center for Drug Evaluation and Research noted that the levels of NDMA are equivalent to what you might be exposed to while eating common foods like grilled or smoked meats. However, some versions of ranitidine (the generic form of Zantac) contained as much as nine times the acceptable limit for NDMA.

The FDA’s tests simulated how the drug reacts in a person’s stomach and small intestines. The next step is testing the drugs in human patients to fully understand the relationship with NDMA.

Discover Our Content Hub
Access Healthcare Packaging's free educational content library!
Unlock Learning Here
Discover Our Content Hub
Test Your Supply Chain Smarts
Take Healthcare Packaging's supply chain quiz to prove your knowledge!
Take Quiz
Test Your Supply Chain Smarts